linjc16/ctgov huggingface dataset:
Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effect of inhaled anesthetic drugs upon diastolic heart function (heart suction and filling performance) in patients who are undergoing coronary bypass surgery.

Detailed Description
-----------------
Diastolic heart dysfunction is a significant cause of cardiovascular morbidity and is the cause of symptomatic heart failure in approximately one half of patients who are admitted to hospitals with heart failure symptoms. However, diastolic heart function remains difficult to measure objectively without cardiac catheterization. Diastolic heart dysfunction is also common among patients undergoing coronary bypass grafting (CABG) surgery. Despite the ubiquitous use of inhaled volatile drugs to maintain anesthesia in these patients, their effects upon diastolic heart function remain unclear.

Official Title
-----------------
Changes in Diastolic Dysfunction With the Onset of Volatile Anesthesia in Patients Undergoing Coronary Artery Bypass Grafting as Determined by a Load-independent Efficiency Index Derived From the Parameterized Doppler Analysis of Left Ventricular Filling

Conditions
-----------------
Diastolic Dysfunction, Coronary Artery Disease, General Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-emergent coronary bypass grafting surgery Left ventricular ejection fraction of 40% or greater Exclusion Criteria: Myocardial infarction within 4 weeks Greater than mild cardiac valvular pathology Body mass index greater than 35 Cardiac dysrhythmias or pacemaker therapy Left bundle branch block Uncontrolled gastroesophageal reflux disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diastolic efficiency index (derived from the parameterized analysis of transmitral early filling Doppler using the paradigm of the ventricle as a damped harmonic oscillator) |  | Following induction of volatile anesthesia | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diastolic efficiency index (derived from the parameterized analysis of transmitral early filling Doppler using the paradigm of the ventricle as a damped harmonic oscillator) |  | Following the onset of controlled ventilation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diastole, physiopathology, coronary artery disease, volatile anesthetic, sevoflurane
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Study Overview
=================
Brief Summary
-----------------
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.

Official Title
-----------------
Distribution of Risk Factors Amongst Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

Conditions
-----------------
Glaucoma, Open-Angle, Ocular Hypertension

Intervention / Treatment
-----------------
* Other: There is no intervention in this study.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed at study visit or within 3 months of visit with OH OAG (to include POAG, NTG, pigmentary and pseudoexfoliation glaucoma) Exclusion Criteria: No prior treatment for OH or OAG No prior ocular surgery or history of ocular trauma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| There is no intervention in this study<br>This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada. | Other: There is no intervention in this study.<br>* This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the presence and distribution of risk factors in subjects diagnosed with OH or OAG stratified according to geographic distribution in a Canadian population in the ophthalmologist practice. |  | duration of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe the severity of disease at the time of diagnosis and to determine if there is a correlation between risk factors, or number of risk factors, and the severity of disease at presentation. |  | duration of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma, Open-Angle Ocular Hypertension Risk factors Canadian
Upper Extremity Force-velocity Profile in Swimmers

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to measure the changes in the upper extremity force-velocity profile of young swimmers at different training periods during a training season

Detailed Description
-----------------
Tested at each experimental test time point (Baseline: E1, post-general preparation: E2, post-specific E3 and post-competition season: E4). To measure the upper extremity force-velocity parameters, the countermovement push-up test was performed using the force plate

Official Title
-----------------
The Effect of Training Periodization on the Upper Extremity Force-velocity Profile in Swimmers During a Macro Cycle

Conditions
-----------------
Upper Extremity Injury

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 15-18 age go to training regularly Exclusion Criteria: upper extremity surgery in the last 1 year pain during the tests

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|Observational during 16 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The change in the parameters of the force (Newton) obtained from the force platform with countermovement push up from the baseline to the end of the season. | Tested at each experimental test time point (Baseline: E1, post-general preparation: E2, post-specific E3 and post-competition season: E4). To measure the upper extremity force-velocity parameters, the countermovement push-up test was performed using the force plate. | Baseline: E1, (week 0) post-general preparation: E2 (week 6), post-specific E3 ( week12) and post-competition season: E4 (week 16). | 
| velocity (m/s) | Tested at each experimental test time point (Baseline: E1, post-general preparation: E2, post-specific E3 and post-competition season: E4). To measure the upper extremity force-velocity parameters, the countermovement push-up test was performed using the force plate. | Baseline: E1, (week 0) post-general preparation: E2 (week 6), post-specific E3 ( week12) and post-competition season: E4 (week 16). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
swimming, performance, strength, plyometric
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

Official Title
-----------------
Voiding Efficiency, a Predictor of CIC

Conditions
-----------------
Urinary Bladder, Overactive

Intervention / Treatment
-----------------
* Biological: onabotulinumtoxinA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with documented idiopathic OAB diagnosis Patient was treated with 100-200U of BOTOX® for OAB Urodynamics assessment within prior to first BOTOX® injection. Exclusion Criteria: Patient had received botulinum toxin formulations other than BOTOX® in the bladder Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BOTOX®<br>Participants who received 100 to 200 units (U) onabotulinumtoxinA (BOTOX®) as treatment for OAB. No study drug is administered in this study. | Biological: onabotulinumtoxinA<br>* onabotulinumtoxinA (BOTOX®)100 to 200 U<br>* Other names: BOTOX®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pre-BOTOX® Injection VE Cutoff-Ratios that Predict the Risk of CIC following Treatment with 100-200U of BOTOX® | VE was calculated as the ratio of voided volume to the total bladder capacity. | Pre-BOTOX® Injection (Baseline) | 
| Length of Time of CIC Use in Clinical Practice after Treatment with 100-200U BOTOX® |  | 12 Weeks |
Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet

Study Overview
=================
Brief Summary
-----------------
Large population studies of hypopituitary adults (patients with pituitary gland failure) on conventional hormone replacement, but not growth hormone, have an approximate two fold increase in death rate (mortality). The vast majority of this excess mortality relates to vascular disease. While it is possible that overreplacement with steroids, underreplacement with thyroid hormones and sex hormone deficiency contribute, there are increasing data to support a role for GH in the cause of the excess vascular risk. Although a number of surrogates of vascular risk are described in patients with GH deficiency (GHD), how these translate mechanistically into atherothrombotic (blockage of the arteries) disease has not been fully elucidated. This proposed study will analyse both traditional (body composition, serum lipids, handling of sugars)and more complex markers (inflammation, procoagulation, fibrinolysis) of vascular risk/disease. In addition the study will examine 24hr blood pressure, arterial wall thickness, clot structure and function, as well as platelet action. Measurements will be performed at baseline and will be reassessed after patients have been on a stable dose of GH replacement for at least three months. The results of the study will characterise risk factors for vascular disease, and take this a step further to elucidate how these changes translate mechanistically in to vascular damage.

Conditions
-----------------
Hypopituitary Adults

Intervention / Treatment
-----------------
* Drug: Growth Hormone Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Able to give written consent Adults with confirmed GHD (Insulin stimulation test <3ug/L) Other hormone replacement therapy stable for at least three months Exclusion Criteria: active malignancy an acute vascular event within three months of the study any therapy other than hormone replacement serum creatinine >120 micromol/l abnormal LFTs (ALT>3 fold upper limit of normal)

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Growth Hormone Therapy<br> | Drug: Growth Hormone Therapy<br> <br> |
| Control Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Turbidity analysis. |  | up to 3 years |
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage

Official Title
-----------------
Phase III Safety and Efficacy Study of Vitrase (Ovine Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage

Conditions
-----------------
Vitreous Hemorrhage, Diabetic Retinopathy

Intervention / Treatment
-----------------
* Drug: Vitrase
* Drug: Vitrase
* Drug: Vitrase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present >/= 1 month by history or exam BCVA is worse than 20/200 at time of screening Exclusion Criteria: Corneal or lenticular abnormalities that preclude fundus observation Ongoing ocular infection, inflammation or history of herpetic corneal lesion Current or prior retinal detachment or retinal tears or breaks or intraocular tumor More than 1 severe vitreous hemorrhage within 6 months Previous vitrectomy for any reason Hemorrhage is exclusively pre-retinal, or old & organized Prior Vitrase for intravitreal injection in either eye No light perception in either eye at any time Known contraindications to study medication Sickle cell disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitrase<br>A single dose of 0.05 cc of Vitrase (hyaluronidase) for ophthalmic intravitreal injection is injected into the vitreous chamber. | Drug: Vitrase<br>* 7.5 IU of Vitrase<br>* Other names: ovine hyaluronidase;Drug: Vitrase<br>* 55 IU of Vitrase<br>* Other names: ovine hyaluronidase;Drug: Vitrase<br>* 75 IU of Vitrase<br>* Other names: ovine hyaluronidase;|
| No Intervention: Observation<br>Observation only, no medication or intravitreal injection | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resolution of Vitreous Hemorrhage | Laser treatment of underlying cause of vitreous hemorrhage, or other surgical treatment, or documented evidence of macula & at least 180 degrees of vitreous base, that vitreous hemorrhage cause is resolved | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of complications & adverse events |  | 12 months | 
| Visual Acuity | Best correct visual acuity (BCVA) | 3 months, 6 months, 12 months |
Plantar Compartment Block in Hallux Valgus Ambulatory Surgery

Study Overview
=================
Brief Summary
-----------------
Hallux valgus surgery is known as a painful surgery. Qualitative pain management is the key to successful early recovery and rehabilitation. Popliteal sciatic nerve block is widely used despite the risk of falling due to prolonged motor blockade. Plantar block combined with distal peroneal block may be a better analgesic option in order to provide fast track rehabilitation. The purpose of this study is to describe the analgesic effect of the plantar compartment block following hallux valgus surgery.

Official Title
-----------------
Analgesia Quality and Quality of Deambulation of the Plantar Compartment Block After Hallux Valgus Ambulatory Surgery.

Conditions
-----------------
Hallux Valgus Ambulatory Surgery

Intervention / Treatment
-----------------
* Procedure: Regional anesthesia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 75 years old patient covered by social health insurance have signed written informed consent scheduled for hallux valgus ambulatory surgery Exclusion Criteria: protected patients or patients incapable of giving written informed consent pregnant or breastfeeding woman vulnerable adult inability to participate in pain scoring scales severe coagulopathy allergy or contraindications to study drugs preopérative gait disorders chronic kidney disease with glomerular filtration rate (GFR) ≤ 50 ml/min (estimated by the Cockroft and Gault formula) severe chronic liver disease chronic pain (treated by non steroidal anti inflammatory drugs, opioids, neuroleptic drugs, antidepressant or anticonvulsants) peripheral neuropathy intervention under general anesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesia quality of the plantar compartment block | after Hallux Valgus ambulatory surgery | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of deambulation | 48 hours | Quality of deambulation during the first 2 postoperative days. | 
| postoperative analgesic | 48 hours | postoperative analgesic requirement, during the first 2 postoperative days. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early ambulation, Plantar block
Corneal Changes After Retinal Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the corneal changes after performing 20 gauge vitrectomy associated with scleral buckling for the treatment of rhegmatogenous retinal detachment.

Detailed Description
-----------------
Patients submitted to 20-gauge vitrectomy associated with scleral buckling were evaluated with corneal topography before surgery and in the 7,30 and 90 days after surgery to asses corneal curvature changes.

Official Title
-----------------
Corneal Topographic Changes After 20-gauge Pars Plana Vitrectomy Associated With Scleral Buckling for the Treatment of Rhegmatogenous Retinal Detachment

Conditions
-----------------
Rhegmatogenous Retinal Detachment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with rhegmatogenous retinal detachments Exclusion Criteria: Previous eye surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Preoperative Corneal Thickness and Postoperative Visual Outcomes After Posterior Lamellar Corneal Transplant

Study Overview
=================
Brief Summary
-----------------
To evaluate the impact of preoperative corneal thickness on visual outcomes following Descemet's stripping endothelial keratoplasty (DSAEK) or Descemet membrane endothelial keratoplasty (DMEK)

Detailed Description
-----------------
Patients underwent DSAEK or DMEK for endothelial dysfunction, from October 2013 to November 2016. Patients aged > 18 years and with an indication for posterior lamellar graft surgery, such as Fuchs dystrophy, were included. Exclusion criteria included a history of penetrating keratoplasty in the study eye and a need for a penetrating keratoplasty following endothelial graft failure. Visual acuity, central corneal thickness (CCT) and graft thickness were measured preoperatively, and at postoperative day 7 and months 1, 3 and 6.

Official Title
-----------------
Relationship Between Preoperative Corneal Thickness and Postoperative

Conditions
-----------------
Corneal Changes of Membranes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinically indicated need for posterior lamellar graft surgery (DSAEK or DMEK) such as: Fuchs dystrophy, pseudophakic bullous decompensation or other endothelial dysfunction corneal Exclusion Criteria: were a history of penetrating keratoplasty in the indicated eye the technical inability of preoperative CCT measurement the need for a penetrating keratoplasty following endothelial graft failure severe postoperative complications resulting in unquantifiable visual acuity

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Descemet's stripping endothelial keratoplasty (DSAEK) or Descemet membrane endothelial keratoplasty (DMEK) | LogMar | month 6 |